Shots:
- Ocugen has reported preliminary 12mos. data from its P-II (ArMaDa) trial (n=51) of OCU410 (AAV5-RORA) in GA secondary to dry AMD, with ~50% of pts evaluated to date
- Trial showed a 46% reduction in GA lesion growth vs control (medium + high dose), with the medium dose achieving a 54% reduction; 50% pts achieved >50% lesion size reduction, & subgroup (n=14; pts with ≥7.5 mm2 ) showed a 57% greater lesion reduction
- Also, P-I data (N=9) showed 60% slower ellipsoid zone loss in OCU410-treated eyes vs untreated eyes at 12mos., with reduced EZ-RPE loss. Ocugen plans to report full P-II data by late Q1’26 & begin P-III development in 2026, with BLA filing planned for 2028
Ref: Ocugen | Image: Ocugen | Press Release
Related News: Ocugen Joins Forces with Kwangdong Pharmaceutical for OCU400 to Treat Retinitis Pigmentosa
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
